Program
JY231
A development code. Also written as “JY231 Injection” and “JY231 (JY231 injection)”.
Its studies are mostly in Autoimmune Diseases · Burkitt Lymphoma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shenzhen Genocury Biotech | 22 open or running | no phasesince Nov 5, 2024 | Nov 5, 2024 | Dec 2027NCT06890065 |
| LiangZou | 11 open or running | no phasesince Jul 1, 2025 | Jul 1, 2025 | Dec 31, 2026NCT07059169 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 5, 2024First study: no phase study in B-NHLNew to Shenzhen Genocury BiotechShenzhen Genocury Biotech · NCT06678282 · 20 planned · China
- Mar 16, 2025No phase study in Burkitt LymphomaShenzhen Genocury Biotech · NCT06890065 · 20 planned · China
- Jul 1, 2025LiangZou's first study: no phase study in Autoimmune DiseasesNew to LiangZouLiangZou · NCT07059169 · 20 planned · China
Ahead
- Dec 31, 2026Primary completion: no phase study in Autoimmune DiseasesLiangZou · NCT07059169
- Dec 2027Primary completion: no phase study in Burkitt LymphomaShenzhen Genocury Biotech · NCT06890065
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07059169Autoimmune Diseases · China | – | Recruiting | LiangZou | Dec 31, 2026 | 20 |
| NCT06890065Burkitt Lymphoma · China | – | Recruiting | Shenzhen Genocury Biotech | Dec 2027 | 20 |
| NCT06678282B-NHL · China | – | Recruiting | Shenzhen Genocury Biotech | Sep 30, 2026 | 20 |
How it is read
Names in the registry
- “JY231 Injection”, 2 entries
- “JY231 (JY231 injection)”, 1 entry
Codes read as this program: JY231.
Conditions, from the studies’ own filings
- Autoimmune Diseases, 1 study
- Burkitt Lymphoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.